Thomas Waldmann, Chief, NCI to Give Keynote Talk at Immunodiagnostics & Immunomonitoring Conference
Summary
IL-2R alpha (CD25) targeted therapy with monoclonal antibodies has provided effective treatment for leukemia, for autoimmune disorders, and for the prevention of allograft rejection.Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com ### Monrovia, CA, November 22, 2007 --( PR.com )-- Dr. Thomas A. Waldmann, Chief of the Metabolism Branch and Head of Cytokine Immunology and Immunotherapy at the National Cancer Institute will give the Keynote presentation at GTCbio’s 2nd Immunodiagnostics & Immunomonitoring: From Research to Clinic conference on December 6-7, 2007 in Washington D.C.Dr.Waldmann will present on the contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes with implications for immunotherapy of cancer and autoimmune diseases as well as for vaccine design.Monoclonal antibodies have come of age with 19 approved by the FDA.Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
Classifications
AskAI Classifications
LabelsLinked Companies
